A hologram appearing package image

Details for Australian Patent Application No. 2007334023 (hide)

Owner Colgate-Palmolive Company

Inventors Sarnataro, John A.

Agent FB Rice

Pub. Number AU-B-2007334023

PCT Pub. Number WO2008/076785

Priority 60/869,983 14.12.06 US

Filing date 13 December 2007

Wipo publication date 26 June 2008

Acceptance publication date 15 September 2011

International Classifications

B41M 3/00 (2006.01) Printing processes to produce particular kinds of printed work, e.g. patterns

B41M 3/14 (2006.01) Printing processes to produce particular kinds of printed work, e.g. patterns - Security printing

B41M 7/00 (2006.01) After-treatment of printed works, e.g. heating, irradiating

G03H 1/02 (2006.01) Holographic processes or apparatus using light, infra-red, or ultra-violet waves for obtaining holograms or for obtaining an image from them - Details

Event Publications

9 July 2009 PCT application entered the National Phase

  PCT publication WO2008/076785 Priority application(s): WO2008/076785

15 September 2011 Application Accepted

  Published as AU-B-2007334023

19 January 2012 Standard Patent Sealed

17 May 2012 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 03 Apr 2012. Address for service in Australia - FB Rice Level 23 200 Queen Street Melbourne VIC 3000

27 September 2012 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 03 Apr 2012 2008

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007334038-Methods and compositions for treating gastrointestinal disorders

2007334022-Methods and compositions for treating IL-4 or IL-13 related fibrosis related pathologies